Answers are grounded in this paper and cite their sources.
Genotypic resistance to antiretroviral drugs was analysed in plasma from 57 acute or recent HIV seroconverters in Madrid. The overall prevalence of drug-associated primary resistance mutations was 25.8% in 1997–1999, but declined to 3.8% in 2000–2001. The lower rate in recent years suggested that most new HIV infections derive from viraemic individuals unaware of their HIV- positive status, rather than from those failing antiretroviral treatment. Drug-resistance testing is thus not required before beginning antiretroviral therapy. Resistance to antiretroviral drugs represents one of the major obstacles for the success of HIV therapy [1]. Viruses carrying drug-resistant mutations can be transmitted, and can then compromise the response to therapy in drug-naive individuals [2]. In western countries, where most HIV-infected individuals are under antiretroviral therapy, an increase in the prevalence of drug resistance among new HIV-1 seroconverters has been noted in recent years [3–5]. Accordingly, updated guidelines recommend resistance testing before treatment is initiated in individuals with recently acquired HIV infection [2,6]. In Spain, surveillance studies conducted over the past 5 years have demonstrated that the rate of genotypic resistance among drug-naive individuals with chronic HIV infection has declined significantly since 1997 [7–9]. However, data from HIV seroconverters are scarce, although alarming rates of primary resistance have occasionally been reported [4]. In order to analyse the rate of drug-resistance genotypes in newly infected patients since highly active antiretroviral therapies became widely used, we have examined recent HIV seroconverters in Madrid, updating the available results until 1999 [3]. The study included all individuals with documented primary HIV infection identified in two referral HIV centres located in Madrid. It should be noted that in these facilities, more homosexual men than intravenous drug users are often seen, and therefore the data presented may not be extrapolated to the average population of seroconverters in Madrid. The eligibility criteria for an individual to be enrolled in the study were as follows: laboratory evidence of acute primary HIV infection (detectable plasma HIV RNA, together with a negative or indeterminate HIV antibody test) or seropositivity for HIV-1 infection (reactive enzyme-linked immunosorbent assay and Western blot), a negative test being performed within the previous 12 months. The quantification of plasma HIV RNA was performed using a branched DNA assay (Bayer, Barcelona, Spain), according to the manufacturer's instructions. The CD4 T cell lymphocyte count was determined by flow cytometry (Coulter, Madrid, Spain), using fluorescein-labelled antibodies. Genetic sequence analyses of both reverse transcriptase and protease genes were carried out in all plasma specimens using an automatic sequencer (ABI Prism 3100; Applied Biosystems, Foster City, CA, USA). All nucleotide changes considered to be associated with drug resistance by the International AIDS Society – USA Panel [1,10] were recorded. A total of 57 individuals were examined, 26 of them being recruited during 2000 and 2001. The remaining 31 subjects had acquired HIV infection between 1997 and 1999, and all but one of them had been reported previously [3]. Overall, 81% of all subjects were men, and all were Spanish natives. Their mean age was 34 years old (range 25–45). The route of HIV infection had been through homosexual contacts (69%), heterosexual relationships (23%), needle sharing (6%), and blood transfusion (one subject). The demographics of patients belonging to the two different periods did not differ significantly (see Table 1). At the time of genetic sequence analyses, the mean plasma HIV-RNA level was 5.1 log10 copies/ml (range 3.4–5.7) and the mean CD4 T lymphocyte count was 690 cells/μl (range 288–1639).Table 1: Main demographics and rate of genotypic resistance in the study population. The overall prevalence of HIV genotypes associated with reduced drug susceptibility was 25.8% (8/31) in samples collected until 1999. In contrast, it declined to 3.8% (1/26) in individuals who seroconverted thereafter (P = 0.031). The distribution of resistance genotypes was as follows. First, in the period 1997–1999, primary mutations at the reverse transcriptase gene were M41L in four subjects, T215Y in three, M184V in one, and Y181C in one; whereas at the protease gene they were M46L, V82I, and L90M, each in different individuals. In contrast, only one subject harboured a M46L mutation within the protease gene during the period 2000–2001. Of note was the fact that no significant differences in the rate of genotypic resistance were found comparing subjects with acute HIV infection (overall, one third of the total number) and those with recent seroconversion within the same period. All HIV sequences were characterized as belonging to HIV-1 subtype B. The emergence of HIV drug resistance in patients failing antiretroviral therapy is a frequent phenomenon, and the transmission of these HIV-resistant variants has been well documented [11–13]. The prevalence of primary HIV drug resistance seems to be growing in some western countries, currently exceeding 20% in the United States and UK [5,14]. Our data from Spain are quite different. We have noticed a reduction in the rate of primary drug resistance among newly infected individuals, which is mainly caused by a dramatic reduction in the prevalence of resistance genotypes at the reverse transcriptase gene. Resistance genotypes at the protease gene remain relatively stable at a low rate. In a recent study from Switzerland [15], the rate of transmission of HIV-resistant viruses has declined steadily since 1996, currently being around 5%. The authors suggested that the growing number of individuals infected with HIV-1 non-B subtypes (reflecting that most are immigrants), and the higher proportion of patients with undetectable viraemia (and therefore, having very low infectivity) in the Swiss HIV Cohort, may account for their findings. In our study, all virus sequences were characterized as belonging to HIV-1 subtype B in the two different periods. Taking into account the demographics of our study population, we believe that most new infections in Madrid are now occurring in individuals in contact with those who may not be aware of their HIV-positive status. These individuals are not taking antiretroviral drugs (and therefore rarely harbour resistant viruses), and may harbour relatively high levels of viraemia (and therefore should be considered highly infectious). In summary, the rate of primary drug resistance among newly HIV-infected individuals in Madrid seems to be declining. Therefore, drug resistance testing in recent HIV seroconverters does not seem to be required before beginning antiretroviral therapy. New approaches to encourage safer sexual behaviour and HIV screening are urgently needed. Carmen de Mendozaa Jorge del Romerob Carmen Rodríguezb Angélica Corrala Vincent Sorianoa Acknowledgement The authors would like to thank Dr Gonzalez-Lahoz for his continuous support.
No takes yet. Share an insight, caveat, or question.
Mendoza et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: